Panacea Biotec Limited (PANACEABIO.NS)
INR 463.0
(1.47%)
INR 463.0
(1.47%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 209.9 Million INR | 4.12% |
| 2022 | 201.6 Million INR | -40.88% |
| 2021 | 341.03 Million INR | -95.36% |
| 2020 | 7.35 Billion INR | 19.89% |
| 2019 | 6.13 Billion INR | 1229.36% |
| 2018 | 461.22 Million INR | -91.92% |
| 2017 | 5.7 Billion INR | -27.22% |
| 2016 | 7.84 Billion INR | -9.57% |
| 2015 | 8.67 Billion INR | 19.93% |
| 2014 | 7.22 Billion INR | 23.97% |
| 2013 | 5.83 Billion INR | -15.47% |
| 2012 | 6.89 Billion INR | 34.61% |
| 2011 | 5.12 Billion INR | -40.76% |
| 2010 | 8.65 Billion INR | 22.64% |
| 2009 | 7.05 Billion INR | 0.35% |
| 2008 | 7.03 Billion INR | 76.37% |
| 2007 | 3.98 Billion INR | 87.17% |
| 2006 | 2.12 Billion INR | -63.67% |
| 2005 | 5.86 Billion INR | 263.81% |
| 2004 | 1.61 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 206.2 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 209.9 Million INR | 4.12% |
| 2023 Q4 | 209.9 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 FY | 201.6 Million INR | -40.88% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 322.8 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 201.6 Million INR | 0.0% |
| 2021 Q4 | 341.03 Million INR | 0.0% |
| 2021 Q2 | 7.34 Billion INR | 0.0% |
| 2021 FY | 341.03 Million INR | -95.36% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 7.35 Billion INR | 19.89% |
| 2020 Q2 | 6.4 Billion INR | 0.0% |
| 2020 Q4 | 7.35 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 6.13 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 6.54 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 6.13 Billion INR | 1229.36% |
| 2018 Q4 | 461.22 Million INR | 0.0% |
| 2018 FY | 461.22 Million INR | -91.92% |
| 2017 FY | 5.7 Billion INR | -27.22% |
| 2016 FY | 7.84 Billion INR | -9.57% |
| 2015 FY | 8.67 Billion INR | 19.93% |
| 2014 FY | 7.22 Billion INR | 23.97% |
| 2013 FY | 5.83 Billion INR | -15.47% |
| 2012 FY | 6.89 Billion INR | 34.61% |
| 2011 FY | 5.12 Billion INR | -40.76% |
| 2010 FY | 8.65 Billion INR | 22.64% |
| 2009 FY | 7.05 Billion INR | 0.35% |
| 2008 FY | 7.03 Billion INR | 76.37% |
| 2007 FY | 3.98 Billion INR | 87.17% |
| 2006 FY | 2.12 Billion INR | -63.67% |
| 2005 FY | 5.86 Billion INR | 263.81% |
| 2004 FY | 1.61 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biocon Limited | 129.32 Billion INR | 99.838% |
| Blue Jet Healthcare Limited | 3.79 Million INR | -5438.259% |
| Concord Biotech Limited | 18.87 Million INR | -1012.348% |
| Dishman Carbogen Amcis Limited | 2.45 Billion INR | 91.454% |
| Jubilant Ingrevia Limited | 4.25 Billion INR | 95.068% |
| Lyka Labs Limited | 429.06 Million INR | 51.08% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.155% |
| SMS Lifesciences India Limited | 331.45 Million INR | 36.672% |
| Supriya Lifescience Limited | 50.2 Million INR | -318.127% |
| Syngene International Limited | 1 Billion INR | 79.01% |
| TAKE Solutions Limited | 7.5 Million INR | -2698.667% |
| Zota Health Care Limited | 631.64 Million INR | 66.769% |